Clinical Trial Update: Safety Study of an Aerosolized, Recombinant Alpha 1-Antitrypsin in Subjects With Alpha 1-Antitrypsin Deficiency [Phase 1, Phase 2]

View source ↗

Summary

Summary of a safety study evaluating an aerosolized recombinant alpha1-antitrypsin in individuals with alpha1-antitrypsin deficiency (Phase 1/Phase 2).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alpha-1 Antitrypsin Deficiency

Drugs mentioned

• Aerosolized recombinant alpha1-antitrypsin (alpha-1 antitrypsin)

Snippet

Sponsor: Baxalta now part of Shire | Conditions: Alpha1-antitrypsin Deficiency | Phase 1, Phase 2 | Status: COMPLETED